Oncolytics Biotech ® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients.
Source: Reuters: Health - Category: Consumer Health News Source Type: news